This suggests a role for Rb-loss and hypoxia in NFκB signaling and that activation of the NFκB pathway in prostate cancer may signal a progression to metastatic, castrate-resistant or neuroendocrine disease. Here, NFKB1 is linked to prostate carcinoma.